Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects

ConclusionsIt is concluded that rhNRG-1 is safe and well tolerated in healthy Chinese subjects at the dosing levels used in this study. The severity and frequency of adverse events did not increase with the prolongation of administration time.Clinical Trial RegistrationChinese Clinical Trial Registry (http://www.chictr.org.cn) Identifier No. ChiCTR2000041107.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research